1521-4141/asset/2040_left.gif?v=1&s=92837c2f17424f89abf3f45e2642c107d62e6c04)
1521-4141/asset/EJI_right.gif?v=1&s=bce6d64154702bbe279104b1163baee31019fb77)
Viewpoints on NK cells
Can NK cells be a therapeutic target in human type 1 diabetes?
Article first published online: 31 OCT 2008
DOI: 10.1002/eji.200838851
Copyright © 2008 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
Additional Information
How to Cite
Dotta, F., Fondelli, C. and Falorni, A. (2008), Can NK cells be a therapeutic target in human type 1 diabetes?. Eur. J. Immunol., 38: 2961–2963. doi: 10.1002/eji.200838851
Publication History
- Issue published online: 7 NOV 2008
- Article first published online: 31 OCT 2008
- Manuscript Accepted: 5 SEP 2008
- Manuscript Revised: 2 SEP 2008
- Manuscript Received: 26 AUG 2008
- Abstract
- Article
- References
- Cited By
Keywords:
- Immunotherapy;
- Islet inflammation;
- NK cells;
- Type 1 diabetes
Abstract
Type 1 diabetes is caused by the autoimmune destruction of insulin-producing cells with consequent hyperglycemia and serious chronic complications. Both innate and adaptive immune responses participate in disease pathogenesis. Studies in animal models and in man have shown that NK cells are involved both in disease progression and in disease protection, thus suggesting that NK cells can represent a potential therapeutic target in type 1 diabetes, once the contribution of these cells to islet autoimmunity has been fully elucidated.